Exploring Current and Upcoming Therapies for Hepatocellular Carcinoma
David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.
David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, and consultant medical oncologist in the Department of Surgery and Cancer at Imperial College London, discusses past and current trials that are significant for the hepatocellular carcinoma (HCC) patient population.
Atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated superiority over sorafenib (Nexavar) for overall survival, progression-free survival, overall response rate, and patient-reported outcomes in the IMbrave150 study (NCT03434379). Pinato thinks there is plenty of evidence to show that this combination will make transformative changes to the advanced HCC setting.
Trials that are expected to report data soon for immunotherapy doublets, such as CTLA4 plus PD-1 combinations. These trials are in the frontline setting for patients with HCC. Pinato says that the frontline space will become crowded over the next few months and years. He feels that tyrosine kinase inhibitors (TKIs) will always play a role in the treatment for these patients, but the position of these therapies will shift based on the duration of response, likelihood of response, and extent of clinical benefit in patients. There is interest in this setting on how the introduction of combination immunotherapy might move TKI treatment to a later line of therapy, which has happened in other cancer settings before.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
